

*REMARKS/ARGUMENTS**Discussion of Specification and Claim Amendments*

The specification has been amended to include a reference to [SEQ ID NO: 1] or [SEQ ID NO:2] as appropriate, or to correct obvious typographical errors. The amendment to the paragraph beginning at page 7, line 4 [SEQ ID NO: 2] is supported by the correct formula IV spelled out immediately following the sequence; from page 7, lines 20-21 and the synthetic scheme at page 5. Claim 1 has been amended to improve the form. Claim 6 has been amended to remove "prophylaxis".

No new matter has been added.

*Discussion of Rejections**A. Non-enablement –*

Applicants have amended Claim 6 to remove prophylaxis. Accordingly, the non-enablement rejection has been obviated, and therefore, the rejection should be withdrawn.

*B. Indefiniteness –*

Applicants have amended claim 1 as discussed, which should remove the indefiniteness rejection.

*C. Sequence Listing –*

Applicants herewith submit a replacement Sequence Listing. Accordingly, the requirement has been fulfilled. Applicants request entry of the replacement Sequence Listing.

*Conclusion*

Applicants respectfully submit that the patent application is in condition for allowance. If, in the opinion of the Examiner, a telephone conference would expedite the prosecution of the subject application, the Examiner is invited to call the undersigned attorney.

Respectfully submitted,



---

Xavier Pillai, Reg. No. 39,799  
LEYDIG, VOIT & MAYER, LTD.  
Two Prudential Plaza, Suite 4900  
180 North Stetson Avenue  
Chicago, Illinois 60601-6731  
(312) 616-5600 (telephone)  
(312) 616-5700 (facsimile)

Date: July 14, 2008